Review Article
The Involvement of Phospholipases A2 in Asthma and Chronic Obstructive Pulmonary Disease

Ewa Pniewska and Rafal Pawliczak

Department of Immunopathology, Faculty of Biomedical Sciences and Postgraduate Training, Medical University of Lodz, 7/9 Żeligowskiego Street, Building 2, Room 122, 90-752 Lodz, Poland

Correspondence should be addressed to Rafal Pawliczak; rafal.pawliczak@umed.lodz.pl

Received 25 May 2012; Revised 2 January 2013; Accepted 27 February 2013

Academic Editor: Celeste C. Finnerty

Copyright © 2013 E. Pniewska and R. Pawliczak. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The increased morbidity, mortality, and ineffective treatment associated with the pathogenesis of chronic inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD) have generated much research interest. The key role is played by phospholipases from the A2 superfamily: enzymes which are involved in inflammation through participation in pro- and anti-inflammatory mediators production and have an impact on many immunocompetent cells. The 30 members of the A2 superfamily are divided into 7 groups. Their role in asthma and COPD has been studied in vitro and in vivo (animal models, cell cultures, and patients). This paper contains complete and updated information about the involvement of particular enzymes in the etiology and course of asthma and COPD.

1. Introduction
Both asthma and COPD are airway diseases characterized by impaired airflow in the respiratory tract, chronic airway inflammation, as well as symptoms such as coughing, dyspnea, and wheezing. Intensive studies focused on the pathogenesis of these conditions implicate, among others, the group of phospholipases A2, which possess enzymatic and nonenzymatic properties. This paper presents general information about phospholipases and details the current knowledge about particular phospholipases A2 involved in asthma and COPD in human and animal models. The data regarding interactions between members of this superfamily is summarized, as well as the role of these enzymes in exacerbations of inflammatory diseases.

2. Phospholipases
Phospholipases are enzymes that hydrolyze phospholipids. The main substrates for these enzymes are glycerophospholipids which contain glycerol with a saturated fatty acid in the sn-1 position and an unsaturated fatty acid in the sn-2 position. The phospholipases responsible for hydrolysis of glycerophospholipids are divided into two groups: acylhydrolases and phosphodiesterases. The first group comprises phospholipase A1 (PLA1) and A2 (PLA2), which hydrolyze the ester bond at the sn-1 and sn-2 positions, respectively. The second group comprises phospholipase C (PLC) which cleaves the glycerol-phosphate bond, and phospholipase D (PLD), which liberates phosphatidic acid and alcohol (Figure 1). Phospholipase B shares both the properties of PLA1 and PLA2.

The structure, function, and catalytic mechanism of the enzyme determine its place within the phospholipase A2 superfamily, be it secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2), Ca2+-independent phospholipase A2 (iPLA2), PAF acetylhydrolases (PAF-AH), or lysosomal PLA2 (LPLA2). The latest classification, based on genetic structure, divides these enzymes into groups from I to XVI (in each one, the enzyme is represented by a capital letter) [1]. The characteristic features of each group are presented in Table 1. Table 2 includes information about the mechanism of action and function of particular subgroups of PLA2s concerning physiology and pathophysiology.
3. Asthma and COPD

Currently about 300 million people worldwide suffer from asthma, and in 2025, this number is expected to grow by another 100 million. Annually, about 250 000 people die from asthma [2]. Asthma is defined according to the GINA (Global Initiative for Asthma) [3] as a chronic airway inflammatory disease in which many cells and cellular elements are involved. Chronic inflammation is a cause of bronchial hyperresponsiveness, leading to recurrent episodes of wheezing, dyspnea, chest tightness, and coughing, occurring particularly at night or dawn. This is usually accompanied by episodes of diffuse bronchial obstruction of varying severity, which often subside spontaneously or with treatment.

According to GOLD (The Global Initiative for Chronic Obstructive Lung Diseases) [6], COPD is characterized by a progressive and poorly reversible airflow limitation caused by both small airway diseases (airway inflammation and destruction) and parenchymal destruction (loss of alveolar attachments and decrease of elastic recall). Also, other extrapulmonary effects, such as weight loss, nutritional abnormalities, skeletal muscle dysfunction influence the severity of the disease. Apart from the genetic background (hereditary alpha-1 antitrypsin deficiency) [7] cigarette smoke is a crucial environmental factor in COPD development [8]; it is responsible for airway inflammation and further oxidant/antioxidant imbalance (oxidative stress) causing amplification of lung inflammation.

4. Analysis of Phospholipases A\textsubscript{2} Involvement in Asthma and COPD

An analysis of studies concerning the profile of PLA\textsubscript{2}s expression in many experimental systems has revealed ambiguous results. Many different inductors used for cells stimulation cause expression of various types of enzymes in the same cells. Also, the presence of heterogeneous cells in experimental systems influences the expression of PLA\textsubscript{2}s [9].

Mast cells, Th\textsubscript{2} lymphocytes, and eosinophils are the most important cellular components of asthma. It has been established that primary human lung mast cells constitutively express mRNA for the IB, IIA, IID, IIE, IIF, III, V, X, XIIA, and XIIB sPLA\textsubscript{2} groups and stimulation with anti-IgE antibodies can induce their secretion [10]. Hence sPLA\textsubscript{2} proteins are believed to belong to preformed mediators which are stored in mast cells granules. Cells stimulation by anti-IgE antibodies causes degranulation of mast cells, and sPLA\textsubscript{2} appears in the early phase of allergic reaction. Muñoz et al. have shown that sPLA\textsubscript{2}V is not expressed in eosinophils in detectable amounts. However exogenous hPLA\textsubscript{2}V can activate eosinophils, inducing the liberation of arachidonic acid (AA) and LTC\textsubscript{4} production [11]. Increased cPLA\textsubscript{2}\textalpha phosphorylation and cPLA\textsubscript{2}\textalpha activity was observed in eosinophils of asthmatics after allergen challenge [12].

Alveolar macrophages and neutrophils play a crucial role in the pathophysiology of COPD [13, 14]. Human macrophages express cPLA\textsubscript{2} IVA, iPLA\textsubscript{2} VIA, and several sPLA\textsubscript{2}s (IIA, IID, IIE, IIF, V, X, and XIIA, but not group IB and IIIIA enzymes). Higher expression of sPLA\textsubscript{2} IIA is observed after LPS treatment [15]. Neutrophils stimulated in vitro by the tripeptide formyl-Met-Leu-Phe (fMLP) demonstrate mRNA and protein expression of sPLA\textsubscript{2} V and sPLA\textsubscript{2} X, where the sPLA\textsubscript{2} V protein is found in azurophilic and specific granules, and sPLA\textsubscript{2} X is found only in azurophilic granules. GIB, GIHA, GIID, GIIE, GIIF, GIII, and GXII sPLA\textsubscript{2}s are undetectable. Cell activation by fMLP or zymosan results in the release of GV but not GX sPLA\textsubscript{2} [16].

The BALF of patients with COPD demonstrates a three- to fivefold higher activity of PLA\textsubscript{2}s in comparison to a control BALF but the protein level shows no difference [17]. No differences in sPLA\textsubscript{2} IIs serum levels exist between healthy smokers and nonsmokers. However, significantly greater levels of this enzyme are found in the BALF of smokers compared with nonsmokers [18]. Among sPLA\textsubscript{2}s, sPLA\textsubscript{2}IID is also considered as a molecule involved in the course of COPD. A change of Gly80Ser in the sPLA\textsubscript{2}IID protein may be associated with body weight loss in patients suffering from COPD [19]. sPLA\textsubscript{2}IID can be also involved in control of inflammation by inhibition of CD4+, CD8+ T cells proliferation and induction of regulatory T cell differentiation [20]. Cigarette smoke extract (CSE) can induce the production of cytosolic phospholipase A\textsubscript{2} in human pulmonary microvascular endothelial cells [21]. Moreover oxidative stress can increase the activity of cPLA\textsubscript{2} by promoting its phosphorylation [22]. cPLA\textsubscript{2} also participates in phosphodiesterase 4 signaling, whose inhibition attenuates neutrophilic inflammation in COPD [23]. The increased values of PLA\textsubscript{2}VII in patients with long-standing pulmonary hypertension (severe complication in COPD) are related to severe endothelial dysfunction [24].

sPLA\textsubscript{2} V plays a different role in the activation of eosinophils and neutrophils. Hence, its involvement in the pathogenesis of asthma and COPD can vary. Exogenous sPLA\textsubscript{2} V can activate the production of AA and leukotrienes in both cell types. However, LTD\textsubscript{4} is preferentially produced in neutrophils, and LTC\textsubscript{4} in eosinophils [11]. The sPLA\textsubscript{2} V-induced activation of neutrophils in contrast to eosinophils requires the presence and activation of cPLA\textsubscript{2} [25]. The inhibition of cPLA\textsubscript{2} may be more effective in diseases where neutrophils...
Table 1: Characteristics of structure and localization of human phospholipase A2 enzymes. Adapted and modified from [1, 4]. The Roman numeral indicates the group, and the capital letter after the number indicates the subgroup.

| Name                  | Members (human) | Molecular mass (kDa) | Relationship with Ca\(^{2+}\) | Catalytic site               | Localization                                      |
|-----------------------|-----------------|----------------------|-----------------------------|------------------------------|---------------------------------------------------|
| **Secretory phospholipase A\(_2\) (sPLA\(_2\))** |                 |                      |                             |                              |                                                   |
| IB (sPLA\(_2\)IB)    |                 | 13–15                |                             |                              | Secreted                                         |
| IIA (sPLA\(_2\)IIA)  |                 | 13–15                |                             |                              | Secreted; membrane; secretory granules            |
| IID (sPLA\(_2\)IID)  |                 | 14–15                |                             |                              | Secreted                                          |
| IIE (sPLA\(_2\)IIE)  |                 | 14-15                |                             |                              | Secreted                                          |
| IIF (sPLA\(_2\)IIF)  |                 | 16-17                |                             |                              | Secreted; Golgi apparatus; nuclear envelope; plasma membrane |
| III (sPLA\(_2\)III)  |                 | 55                   | Dependent                   | Histidine/Aspartic acid       | Secreted; cytoplasm                              |
| V (sPLA\(_2\)V)      |                 | 14                   |                             |                              | Secreted; Golgi apparatus; nuclear envelope; plasma membrane |
| X (sPLA\(_2\)X)      |                 | 14                   |                             |                              | Secreted                                          |
| XIIA (sPLA\(_2\)XIIA)|                 | 19                   |                             |                              | Secreted; cytoplasm                              |
| XIIB (sPLA\(_2\)XIIB, XIII) |             | 20                   |                             |                              | Secreted                                          |
| **Cytosolic phospholipase A\(_2\) (cPLA\(_2\))** |                 |                      |                             |                              |                                                   |
| IVA (cPLA\(_\alpha\))|                 | 85                   | Dependent                   |                              | Nucleus; cytoplasmic vesicles                     |
| IVB (cPLA\(_\beta\))-three splice variants |             | 114                  |                             |                              | Cytosol                                           |
| IVC (cPLA\(_\gamma\))|                 | 61                   | Independent                 |                              | ER; Mitochondrion                                  |
| IVD (cPLA\(_\delta\))|                 | 92-93                |                             | Serine/Aspartic acid/Arginine| Cytosol; Cytoplasmic vesicle membrane; peripheral membrane protein; cytoplasmic side |
| IVE (cPLA\(_\varepsilon\))|             | 96                   | Dependent                   |                              | Cytosol; lysosome membrane; peripheral membrane protein |
| IVF (cPLA\(_\zeta\)) |                 | 95                   |                             |                              | Cytosol; lysosome membrane; peripheral membrane protein; cytoplasmic side |
| **Ca\(^{2+}\)-independent phospholipase A\(_2\) (iPLA\(_2\))** |                 |                      |                             |                              |                                                   |
| VIA-(iPLA\(_\beta\))-five splice variants |             | 84–90                |                             |                              | Cytosol                                           |
| VIB (iPLA\(_\gamma\))-four splice variants |             | 88–91                |                             |                              | ER; peroxisomal and mitochondrial membrane        |
| VIC (iPLA\(_\delta\), NTE) |             | 146                  | Independent                 | Serine | ER; single-pass type I membrane protein; cytoplasmic side |
| VID (iPLA\(_\varepsilon\), adiponutrin) |             | 53                   |                             |                              | Membrane; single-pass type II membrane protein    |
| VIE (iPLA\(_\zeta\))|                 | 57                   |                             |                              | Lipid droplet membrane; single-pass type II       |
| VIF (iPLA\(_\eta\)) |                 | 28                   |                             |                              | membrane; cell membrane                           |
| **Acidic Ca\(^{2+}\)-independent phospholipase A\(_2\) (aiPLA\(_2\))** |             |                      |                             |                              |                                                   |
| aiPLA\(_2\)          |                 | 26                   | Independent                 | Serine                       | Cytoplasm; Lysosome                               |
| **Lysosomal phospholipase A\(_2\)** |             |                      |                             |                              |                                                   |
| XV (LPLA\(_2\), LLPL, ACS) |             | 45                   | Independent                 | Serine/Histidine/Aspartic acid| Secreted; Lysosome                               |
play a crucial role because they indirectly inhibit also the function of sPLA₂.

5. Role of PLA₂s in Asthma and COPD

The proposed mechanism of action of phospholipases A₂ (PLA₂s) in inflammatory diseases includes the liberation of arachidonic acid, generation of lysophospholipids, interaction between enzymes belonging to the A₂ superfamily, surfactant degradation, release of cytokines, and the impact on immunological and inflammatory cells (dendritic cells, T-cells, and leukocytes) [26].

5.1. The Enzymatic Activity of PLA₂s. The enzymatic properties of PLA₂s refer to their phospholipase, lysophospholipase, transacylase, adiponutrin-like, triglyceride lipase, peroxireduction between enzymes belonging to the A₂ superfamily, surfactant degradation, release of cytokines, and the impact on immunological and inflammatory cells (dendritic cells, T-cells, and leukocytes) [26].

Among cytosolic phospholipases A₂, it has been well documented that cPLA₂IVA (cPLA₂α) plays an important role in eicosanoid production. In patients with inherited cPLA₂ deficiency (loss-of-function mutations in both cPLA₂ alleles), a widespread decrease in eicosanoid concentrations has been observed [34]. SHIP, R485H, and K651R mutations in PLA2G4A gene are thought to play a crucial role in this condition. The functional consequences of localized mutations concerning cPLA₂ catalytic activity, Ca²⁺ recruitment, and affinity for the phospholipid membrane have been confirmed in vitro and in cell culture [35]. In patients with severe asthma, the microsatellite fragments (T) and (CA)n in the promoter region of cPLA₂α gene (PLA2G4A) are shorter in comparison to healthy subjects [36]. In addition, asthmatic patients with shorter microsatellite sequences demonstrate greater expression of cPLA₂α mRNA, cPLA₂α protein, PGE₂ and 15-HETE, but not LTC₄ [37]. cPLA₂ participates in intracellular signaling, leading to allergen-induced production of inflammatory cytokines in the PBMC of asthmatics [38]. Hallstrand et al. [39] identified increased expression of three cPLA₂s, including cPLA₂α, cPLA₂β, and cPLA₂γ in induced sputum cells from subjects with asthma and exercise-induced bronchoconstriction. Both cPLA₂β and cPLA₂γ enzymes also participate in eicosanoids biosynthesis [40, 41]. Increased cPLA₂ expression and subsequent PGE₂ production are present in the asthma phenotype. The therapeutic decision to inhibit cPLA₂ in asthmatics may be unclear when considering the role of PGE₂ in airway inflammation. There is some evidence that PGE₂ can act as bronchodilator, as well as an inhibitor of both allergen-induced bronchoconstriction and inflammatory mediators production [42]. It should be noticed that PGE₂ acts through four different types of receptors (EP₁, EP₂, EP₃, and EP₄). Changes in expression and combination of receptor subtypes actions may affect the action of PGE₂ giving it proinflammatory or bronchoprotective outcomes [43–45]. The pleiotropic properties of PGE₂ make it difficult to establish the direct impact of PGE₂ deficiency which appears as a consequence of cPLA₂ inhibition [46]. Moreover, although cPLA₂ is a major enzyme, it is not the only one providing substrates for eicosanoids synthesis; hence it cannot be excluded that other existing pathways can also perform this function.
| Name                          | Mechanism of action                                                                 | Physiology                                                                 | Function                                                                 | Pathophysiology                                                                 | Sources                                                                 
|-------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------
| **Secretory phospholipases A₂ (sPLA₂s)** | (i) Enzymatic (liberation of AA and lysophospholipids) (ii) Autocrine and paracrine action by binding to N-type and M-type receptors or by binding to integrins | (i) Lipid remodeling for membrane homeostasis (ii) Exocytosis (iii) Phagocytosis (iv) Anticoagulant activity (v) Antibacterial activity (Gram-positive and Gram-negative bacteria) (vi) Antifungal and antiviral activity (vii) Parturition (viii) Spinal processing of nociception | (i) Inflammatory diseases (rheumatoid arthritis, adult respiratory distress syndrome, inflammatory bowel disease, and pancreatitis) (ii) Sepsis (iii) Atherosclerosis (foam cell formation) (iv) Cancer (v) Surfactant hydrolysis | Neutrophils, eosinophils, basophils, T-cells, monocytes, macrophages, platelets, mast cells, airway epithelial cells, alveolar type II epithelial cells, |
| **Cytosolic phospholipases A₂ (cPLA₂s)** | (i) enzymatic: lysophospholipase and transacylase activity | (i) AA releasing (ii) Cellular signaling (iii) Parturition (iv) Nociception | (i) Inflammation (ii) Intestinal ulceration (iii) Psoriasis (iv) Acute lung injury (v) Polyposis (vi) Brain injury (vii) Anaphylaxis | Every tissue                                                                 |                                                                 |
| **Ca²⁺-independent phospholipases A₂ (iPLA₂s)** | via, VIB, VIC, VID, VIEVF-phospholipase A₂ activity VIC-lysophospholipase activity VID-adiponutrin-like activity VIE-triglyceride lipase activity VIF-transacylase activity | (i) Remodeling of phospholipids (ii) AA releasing (iii) Protein expression (iv) Acetylcholine-mediated endothelial-dependent relaxation of the vasculature (v) Apoptosis (vi) Insulin secretion (vii) Bone formation (viii) Sperm development (ix) Cell proliferation (x) Activation of Ca²⁺ influx (xi) Axon regeneration in nerve injury (VIA) | (i) Wallerian degeneration (VIA) (ii) regulation of monocyte migration (VIB) (iii) Oxidant-induced cell injury (VIC) (iv) Ischemia-induced ventricular tachyarrhythmias | (i) Alveolar cells (ii) Macrophages (iii) Normal and cancer lung tissue (iv) Neurons |
| **Lysosomal phospholipase A₂** | (i) Acyl-ceramide synthase (ii) Transacylase activity (iii) Lyso phospholipase activity | (i) may be the crucial enzyme of pulmonary surfactant phospholipid degradation by alveolar macrophages | (i) Phospholipidosis (ii) Complement activation (iii) Induced lung injury | (i) Alveolar macrophages (ii) Peripheral blood monocytes |
| **PAF acetylhydrolases (PAF-AH) or Lipoprotein-associated phospholipases A₂** | (i) Phospholipase A₂ activity | (i) Anti-inflammatory properties by hydrolyzing platelet activating factor (PAF) (ii) Protection against oxidative stress (iii) Brain development | (i) Generation of lysophospholipids and fatty acid hydroperoxides (ROS) (ii) Acute respiratory distress syndrome (iii) Marker of coronary heart disease (iv) Miller-Diker lissencephaly | (i) Alveolar macrophages (ii) Epithelial type II cells |
sPLA$_2$s and arachidonic acid accumulate in the BALF of asthmatics after allergen challenge [47, 48]. Despite being specific to the sn-2 bond, sPLA$_2$s play more of a supporting role in AA liberation. Only sPLA$_2$V and sPLA$_2$X can efficiently interact and hydrolyze phospholipids from the outer surface of the cell membrane [9]. In acute and chronic animal asthma models, a deficit of sPLA$_2$X diminishes the features of asthma (eosinophilia, airway hyperresponsiveness to methacholine, airway remodeling, eicosanoids, and Th2 cytokine production) [49].

Hallstrand et al. [50] showed that the expression of sPLA$_2$X predominates in the airway epithelium, and both sPLA$_2$X and sPLA$_2$IIA are the main phospholipases produced by BALF cells. The activity of the sPLA$_2$V protein was found to be greatly lowered and undetectable. They have suggested that sPLA$_2$X is most important among secretory phospholipases. Only sPLA$_2$X, not sPLA$_2$IIA, is correlated with asthma features such as lung function, recruitment of neutrophils in asthmatics [50]. sPLA$_2$X is responsible for production of cysteinyl leukotrienes (cysLTs) which are specific to the features of asthma (eosinophilia, airway hyperresponsiveness to methacholine, airway remodeling, eicosanoids, and Th2 cytokine production) [49].

Limited information suggests a possible anti-inflammatory role of sPLA$_2$X. However, sPLA$_2$X facilitates the polarization toward proasthmatic M2-macrophage phenotype [52]. It is possible that in a proinflammatory environment, that the sPLA$_2$X propeptide is more rapidly converted to an active form that might influence the Th1/Th2 balance [53]. All these factors may suppress its anti-inflammatory action.

Other sPLA$_2$s (IIA, IID, IIE) contain a heparin-binding domain which allows these enzymes to be taken into the cells and further directed to compartments enriched in AA and enzymes responsible for eicosanoid production [54].

In spite of the fact that several studies have confirmed the participation of iPLA$_2$$\beta$ [55] and iPLA$_2$$\gamma$ [56] in AA release and eicosanoid production, there is no data indicating that these enzymes play a direct role in asthma. By the induction of Ca$^{2+}$ influx they can influence the translocation and activity of Ca$^{2+}$-dependent PLA$_2$s isoforms.

Group VII and VIII PAF-AH hydrolyze the short sn-2 residue of PAF (platelet activating factor). As they lack activity against membrane phospholipids with long-chain sn-2 residues, they are unable to release arachidonic acid from membrane phospholipids [57]. They exhibit pro- and anti-inflammatory properties. On the one hand, they inactivate PAF—the proinflammatory mediator—by hydrolyzing it to inactive acetate and lysolipid but on the other hand, they assist in the generation of lysophospholipids and fatty acid hydroperoxides [4]. Stafforini et al. [58] have established that asthmatics have a decreased level of PAF-AH, and that asthma incidence and severity correlate to PAF-AH deficiency in the Japanese population. Also some PAF-AH gene polymorphisms (Ile198Thr and Ala379Val variants) are known to be a risk factors for developing atopy and asthma [59]. Despite positive effects in animal models [60], administration of human recombinant PAF-AH (rPAF-AH) does not reduce both early and late phase of asthmatic response in mild asthmatics challenged with allergens [61].

The enzymatic activity of PLA$_2$s embraces also lysophospholipid generation. Lysophospholipids are biologically active molecules acting through specific receptors. They are a precursor of platelet activating factor (PAF) and lysophosphatidic acid (LPA). LPA is involved in cell adhesion, motility, and survival. In animal models, lysophospholipid receptors are required for proper development and function of the cardiovascular, immune, respiratory, and reproductive systems [62]. Lysophosphocholine and polyunsaturated fatty acids, including AA, can activate cPLA$_2$ and 5-lipoxygenase by increasing Ca$^{2+}$ and inducing cPLA$_2$ phosphorylation, which then leads to LT$\beta$ biosynthesis [25]. Lysophospholipid has nonspecific cytotoxic effect that depends on its concentration (critical micelle concentration). At concentration below their unspecific cytotoxic effect lysophospholipids can induce apoptosis by interrupting the synthesis of phosphatidylcholine [63].

Phospholipases A$_2$ activity is also connected with disturbed lipid homeostasis in the lung. Asthma and other inflammatory lung diseases are characterized by impaired surfactant function [64]. Secretory phospholipases degrade phosphatidylcholine (PC), the main component of the surfactant responsible for maintenance of small airway patency. The generation of lysophospholipids and free fatty acids by sPLA$_2$-mediated PC hydrolysis has been implicated in small airway closure in asthma. sPLA$_2$ action is enhanced by

| Name                          | Mechanism of action                      | Physiology | Function                  | Pathophysiology                      | Sources |
|-------------------------------|------------------------------------------|------------|---------------------------|--------------------------------------|---------|
| Adipose-specific phospholipase A$_2$ | (i) Phospholipase A$_2$ and A$_2$ activity | PHYSIOLOGY | (i) Catalyzes the release of fatty acids from phospholipids in adipose tissue | (i) Obesity (ii) Metabolic syndrome | Adipose tissue |
eosinophilic lysophospholipases that use lysophospholipids as a substrate [65–68]. The presence of iPLA₂ proteins in alveolar macrophages suggests that they might play a role in surfactant degradation [69].

It should be mentioned that some PLA₂s are involved in antibacterial defense thanks to their ability to hydrolyze the lipids of the bacterial membrane. sPLA₂s IIA, V, X, and IB demonstrate bactericidal activity against gram-positive pathogens but the most effective is sPLA₂IIA. Group XII can directly kill E. coli, unlike the other sPLA₂s that require cofactors [70]. This property of phospholipases can be important in bacterial exacerbations of asthma and COPD.

5.2. Nonenzymatic Activity of PLA₂s. The secretory forms of many PLA₂s exert a range of actions in airway inflammation. Apart from their enzymatic activity, they can act as extracellular mediators involved in chemotaxis, cytokine production, and induction of cellular signaling pathways.

Mammalian N-type receptors have been identified for sPLA₂IB and IIA, X and M-type receptors for sPLA₂IB, IIA, IIE, IIF, V, and X [71]. N-type like receptors are present in lungs whereas M-type receptors have been identified in lung and myeloid cells [72]. The binding of sPLA₂s to their M-type receptor deactivates their enzymatic properties [73].

sPLA₂s are stored in intrinsic mast cell granulates and are released after cell activation by IgE and non-IgE stimuli [9]. After exocytosis, they can act in both autocrine and paracrine manners. By interacting with heparan sulphate proteoglycans and M-type receptors, they can induce PGD₂ and LTC₄ production and stimulate the subsequent granulation of mast cells [74]. Granata et al. [17] delivered an evidence that sPLA₂s can act as proinflammatory connections between mast cells and macrophages in the airway. They suggest that the activation of macrophages by sPLA₂s leads to production of proinflammatory cytokines which sustain the inflammatory and immune response, chemokines responsible for recruitment of monocytes and neutrophils, as well as destructive lysosomal enzymes, NO, PGE₂, and metalloproteinases connected with airway remodeling [17]. The sPLA₂s induce β-glucuronidase release and production of IL-6 from human lung macrophages [75]. They influence the migration and adhesion of neutrophils as well as the release of elastase [76, 77]. In eosinophils, sPLA₂ IA and IIA stimulate β-glucuronidase release and cytokine production (IL-6, IL-8) by AA and lysophospholipid generation, by interaction with membrane peptidoglycans via their heparin-binding site, and through binding with specific M-type or N-type receptors [78]. The functions of sPLA₂s receptors require further studies because there are still some missing or equivocal information [52].

5.3. Crosstalk between PLA₂s. The phospholipases can cooperate in mechanism leading to eicosanoid production. sPLA₂ and cPLA₂ interaction is quite well documented [79, 80]. The effect of group IIA and V PLA₂s on H₂O₂-induced AA release is dependent upon the presence of cPLA₂, and the activation of PKC and ERK1/2 in murine mesangial cells. Ofer et al. [81] have described negative feedback between sPLA₂ and cPLA₂ in eicosanoid production. sPLA₂ activation induces production of bronchoconstrictor cysteinyl leukotrienes and suppresses cPLA₂ expression and the subsequent production of bronchodilator PGE₂. Recently it has been established that in human eosinophils, sPLA₂ initiates Ser(505) phosphorylation of cPLA₂α and stimulates leukotriene synthesis through involvement of p38 and JNK MAPK, cPLA₂α, and 5-lipoxygenase activation, which may be an important process also in airways of asthmatics [51]. Also in bone-marrow-derived mast cells, sPLA₂ mediates the selective release of AA by binding M-type receptors and then inducing MAPK signaling pathways that lead to cPLA₂ activation [82].

5.4. PLA₂s in the Exacerbation of Disease. Another aspect of phospholipases and the asthma/COPD relationship is the participation of these enzymes in the pathogenetic mechanisms of disease exacerbation caused by bacterial factors. This role relates to increased expression of selective PLA₂s, modulation of their activity and involvement in cellular signaling. Elevated cPLA₂α expression was found in primary human lung macrophages after LPS treatment [15, 83]. LPS stimulates expression of cPLA₂ and COX-2 in macrophages, leading to increased production of AA and PGE₂ [83]. LPS treatment was also followed by rapid changes in cPLA₂ phosphorylation [84, 85]. This is one of the mechanisms of regulating enzyme activity [86]. The LPS-phosphorylated form of cPLA₂ is present in induction of iNOS and TNF-α expression [87, 88] and metalloproteinase production [89]. Selective sPLA₂ contributes to LPS-intracellular signaling in liver macrophages [84, 90, 91].

In mice with LPS-induced lung inflammation, the expression of sPLA₂X remains the same before and after treatment. In this study, increased expression of sPLA₂IID and sPLA₂V has been observed, as well as decreased sPLA₂IIE and sPLA₂IIIF levels in the lungs. In rats, sPLA₂IA was seen to have the highest expression after LPS administration [92]. In msPLA₂X−/− mice with knock-in of human sPLA₂X (hsPLA₂X), allergen-induced inflammatory cell recruitment into airways (eosinophils) was restored, as well as hyperresponsiveness to methacholine. The application of specific hsPLA₂X inhibitor (RO 061606) significantly attenuates airway inflammation symptoms, mucous secretion, and hyperresponsiveness [93]. In sPLA₂V−/− knock-out mice, sPLA₂V has been proven to play a role in the development of lung injury and neutrophilic inflammation after bacterial stimulus (LPS) [94]. In addition, sPLA₂V was seen to be connected with regulation of cell migration and generation of airway hyperresponsiveness after ovalbumin challenge [95]. In a murine allergen-challenged asthma model, administration of rPAF-AH is effective in blocking late-phase pulmonary inflammation [60].

6. The Clinical Significance of Studying the Participation of PLA₂s in Airway Inflammatory Diseases

Taking into consideration the severe asthma phenotype, the difficulties related to obtain asthma control utilizing currently
available treatments and the progressive character of inflammation in patients with COPD that increases the morbidity, it seems reasonable to study the differences in pathogenesis of the diseases conditions, especially in relation to possible new therapies and drugs. The PLA$_2$s are an interesting object of study for several reasons. The superfamily of these enzymes contains approximately 30 members that have similar and isoform-specific properties. It has been confirmed that they are strictly connected with inflammation. The inhibitors of particular PLA$_2$s show the positive effect in treatment of inflammatory diseases [96] and they inhibit allergic reaction in vitro [38]. The cPLA$_2$$\alpha$ that evolved together with receptors for eicosanoids, present only in vertebrate, seems to play crucial role in course of inflammation. Its inhibitors such as efpladib [97] and ecpladib [98] successfully inhibit inflammation in rheumatoid arthritis and osteoporosis. The inhaled form of cPLA$_2$$\alpha$ inhibitor, the PLA-950, is considered as potential new treatment in asthmatic patients as well as other PLA$_2$s can influence the function of cPLA$_2$$\alpha$ or have similar effects. Recent studies report positive results of a preclinical evaluation of a cPLA$_2$$\alpha$ inhibitor [99]. The studies and analysis of protein involved in regulation of particular sPLA$_2$ involved in inflammatory diseases could result in finding new target for drugs.

Since 1980, it has been known that glucocorticoids (GCs) can inhibit the activity of PLA$_2$ [100]. The underlying mechanism concerns induction of mRNA and protein expression of lipocortin 1 (annexin 1) and the PLA$_2$ inhibitory protein [101–104]. The structure, function, and mechanism behind the anti-inflammatory action of annexin 1 have been well described elsewhere [105]. Glucocorticoids can also suppress the production of sPLA$_2$ IIA by blocking mRNA synthesis and posttranslational expression in rats [106]. It is questionable whether therapeutic doses of glucocorticoids have sufficient power to satisfactorily inhibit the activity of PLA$_2$. Juergens et al. [107] demonstrated that topical GCs at therapeutically relevant concentration ($10^{-8}$ M) inhibit the spontaneous activity of cPLA$_2$ in the range of 8.6–17.3% depending on the type of GC. They suggest also that this effect may appear as a consequence of a decreased ability to binding the receptors by GCs present in airway in subtherapeutical doses. Although it has been established that treatment with GCs can indirectly inhibit cPLA$_2$ and AA-derivates production resistance to GCs in patients with asthma and COPD could also be problematic. Moreover the GCs have systemic effects and long-term application can cause the side effects. The approach to attack the inflammation process more precisely and downstream (inhibition the eicosanoids production) seems to be rationale.

Another aspect regarding annexin 1 and PLA$_2$s is their cell-specific manner of interactions [105]. Kwon et al. [108] demonstrated that cleavage of annexin 1 causes phosphorylation of cPLA$_2$ during mast-cell activation. Hence it is not clear whether GCs-induced expression of annexin always leads to inhibition of cPLA$_2$ activity. Posttranslational changes can dramatically influence the primary protein function. As previous studies indicate that GCs can stimulate expression of cPLA$_2$ in amnion fibroblast it cannot be excluded that in some specific circumstances GCs may directly induce cPLA$_2$ [109, 110].

7. Conclusions

Previous studies confirm the involvement of phospholipases A$_2$ in asthma and COPD although there are some gaps relating to the roles of specific enzymes. The participation of PLA$_2$ in asthma pathogenesis has been better investigated. The diagnostic problems concerning the overlap syndrome that shares the features of asthma and COPD demand further studies on the pathogenesis of these diseases. The phospholipases A$_2$ through their involvement in the course of inflammation seem to be important aspects of this investigation. As they demonstrate pro- and anti-inflammatory properties, a detailed analysis of their role should act as a focus for further studies intended to bring new insights into the pathogenesis of the diseases and identify targets for new drugs.

Data from studies focused on role of PLA$_2$s in inflammatory diseases facilitate the understanding of molecular aspects of inflammation. It can be observed that cPLA$_2$ plays a main role in eicosanoid production and other PLA$_2$s may influence their activity thanks to enzymatic properties or act as regulators of inflammation through their nonenzymatic activity. The pleiotropic properties of single phospholipase and their differential expression in many cells confirm that this is well-organized network of interaction, and further studies focused on this aspect may provide more useful knowledge. A comparison of how this network works in different inflammatory diseases, as well as in healthy subjects may indicate a key molecule, whose activity or presence will be a diagnostic parameter or whose activation or inhibition will have therapeutic value.

Asthma and COPD are heterogeneous diseases and current treatment gives only the possibility to obtain the phenotype of well-controlled diseases. Analysis of data regarding the involvement of PLA$_2$s in course of diseases arises the concept to use combined therapy rather than the treatment based on inhibition of one of them. The results from preclinical studies of cPLA$_2$ inhibitors are promising but clinical trials will give concrete knowledge about the effectiveness and possible side effects.

Acknowledgments

This paper was partially funded by Polish National Science Centre Grant no. DEC-2012/05/N/Z52/02630 and Medical University of Lodz Grants: 502-03/0-149-03/502-04-004 and 503/0-149-03/503-01 and was supported from science budget for years 2010-2013 as research project (N N402 516939).

References

[1] R. H. Schaloske and E. A. Dennis, “The phospholipase A$_2$ superfamily and its group numbering system,” Biochimica et Biophysica Acta, vol. 1761, no. 11, pp. 1246–1259, 2006.

[2] M. Masoli, D. Fabian, S. Holt, and R. Beasley, “The global burden of asthma: executive summary of the GINA Dissemination Committee Report,” Allergy, vol. 59, no. 5, pp. 469–478, 2004.
[3] Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), May 2012, http://www.ginasthma.org.

[4] E. Kitisoli, G. Nakos, and M. E. Lekka, ”Phospholipase A₂ subclasses in acute respiratory distress syndrome,” Biochimica et Biophysica Acta, vol. 1792, no. 10, pp. 941–953, 2009.

[5] J. E. Burke and E. A. Dennis, ”Phospholipase A₂ structure/function, mechanism, and signaling,” Journal of Lipid Research, vol. 50, pp. S237–S242, 2009.

[6] The Global Initiative for Chronic Obstructive Lung Disease (GOLD), May 2012, http://www.goldcopd.com/

[7] H. Nakamura, ”Genetics of COPD,” Allergology International, vol. 60, no. 3, pp. 253–258, 2011.

[8] E. K. Silverman and F. E. Speizer, ”Risk factors for the development of chronic obstructive pulmonary disease,” Medical Clinics of North America, vol. 80, no. 3, pp. 501–522, 1996.

[9] G. Lambeau and M. H. Gelb, ”Biochemistry and physiology of mammalian secreted phospholipases A₂,” Annual Review of Biochemistry, vol. 77, pp. 495–520, 2008.

[10] M. Ichinose, ”Differences of inflammatory mechanisms in asthma and COPD,” Allergology International, vol. 28, no. 3, pp. 558.e3–565.e3, 2009.

[11] N. M. Muñoz, Y. J. Kim, A. Y. Meliton et al., ”Human group V phospholipase A₂ induces group IVA phospholipase A₂-independent cysteinyl leukotriene synthesis in human eosinophils,” Journal of Biological Chemistry, vol. 278, no. 40, pp. 38813–38820, 2003.

[12] M. C. Seeds, K. K. Peachman, D. L. Bowton, K. L. Siverton, and F. H. Chilton, ”Regulation of arachidonate remodeling enzymes impacts eosinophil survival during allergic asthma,” American Journal of Respiratory and Critical Medicine, vol. 124, no. 3, pp. 358–366, 2009.

[13] P. J. Barnes, ”Alveolar macrophages as orchestrators of COPD,” Journal of Chronic Obstructive Pulmonary Disease, vol. 1, no. 1, pp. 59–70, 2004.

[14] M. Ichinose, ”Differences of inflammatory mechanisms in asthma and COPD,” Allergology International, vol. 58, no. 3, pp. 307–313, 2009.

[15] G. Giannattasio, Y. Lai, F. Granata et al., ”Expression of phospholipases A₂ in primary human lung macrophages. Role of cytosolic phospholipase A₁-α in arachidonic acid release and platelet activating factor synthesis,” Biochimica et Biophysica Acta, vol. 1791, no. 2, pp. 92–102, 2009.

[16] N. Degouesse, F. Ghomashchi, E. Stefanski et al., ”Groups IV, V, and X phospholipases A₂ s in human neutrophils. Role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis,” Journal of Biological Chemistry, vol. 277, no. 7, pp. 5061–5073, 2002.

[17] E. Granata, V. Nardicchi, S. Loffredo et al., ”Secreted phospholipases A₂: a proinflammatory connection between macrophages and mast cells in the human lung,” Immunobiology, vol. 214, no. 9-10, pp. 811–821, 2009.

[18] J. I. Yamashita, M. Ogawa, and T. Shirakusa, ”Increased expression of membrane-associated phospholipase A₂ in the lower respiratory tract of asymptomatic cigarette smokers,” Respiratory Medicine, vol. 90, no. 8, pp. 479–483, 1996.

[19] A. Igarashi, Y. Shibata, K. Yamauchi et al., ”Gly80Ser polymorphism of phospholipase A₂-IID is associated with cytokine inducibility in A549 cells,” Respiration, vol. 78, no. 3, pp. 312–321, 2009.

[20] C. E. Von Allmen, N. Schmitz, M. Bauer et al., ”Secretory phospholipase A₂-IID is an effector molecule of CD4+ CD25+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 28, pp. 11673–11678, 2009.

[21] S. P. Nana, J. D. Lee, S. Sotto-Santiago et al., ”Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 7, pp. 676–685, 2007.

[22] R. Pawliczak, ”The role of radical oxygen species in airway inflammation,” Polski Merkuriusz Lekarski, vol. 14, no. 84, pp. 493–496, 2003.

[23] A. Y. Meliton, N. M. Muñoz, A. Lambertino et al., ”Phosphodiesterase 4 inhibition of β2-integrin adhesion caused by leukotriene B₄ and TNF-α in human neutrophils,” European Respiratory Journal, vol. 28, no. 5, pp. 920–928, 2006.

[24] C. Tanaseanu, S. Tudor, I. Tamsulea, D. Marta, G. Manea, and E. Moldoveanu, ”Vascular endothelial growth factor, lipoprotein-associated phospholipase A₂, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erythematous,” European Journal of Medical Research, vol. 12, no. 4, pp. 145–151, 2007.

[25] Y. J. Kim, K. P. Kim, S. K. Han et al., ”Group V phospholipase A₂ induces leukotriene biosynthesis in human neutrophils through the activation of group IVA phospholipase A₂,” Journal of Biological Chemistry, vol. 277, no. 39, pp. 36479–36488, 2002.

[26] D. L. Bowton, A. A. Dmitrienko, E. Israel, B. G. Zeiher, and G. D. Sides, ”Impact of a soluble phospholipase A₂ inhibitor on inhaled allergen challenge in subjects with asthma,” Journal of Asthma, vol. 42, no. 1, pp. 65–71, 2005.

[27] E. A. Dennis, ”Phospholipase A₂ in eicosanoid generation,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, part 2, pp. S32–S35, 2000.

[28] T. J. Shuttleworth, ”Arachidonic acid activates the noncapacitative entry of Ca²⁺ during [Ca²⁺]i oscillations,” Journal of Biological Chemistry, vol. 271, no. 36, pp. 21720–21725, 1996.

[29] M. N. Graber, A. Alfonso, and D. L. Gill, ”Ca²⁺ pools and cell growth: arachidonic acid induces recovery of cells growth-arrested by Ca²⁺ pool depletion,” Journal of Biological Chemistry, vol. 271, no. 2, pp. 883–888, 1996.

[30] C. D. Funk, ”Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–1875, 2001.

[31] M. Uddin and B. D. Levy, ”Resolvins: natural agonists for resolution of pulmonary inflammation,” Progress in Lipid Research, vol. 50, no. 1, pp. 75–88, 2011.

[32] A. Planagumà, S. Kazani, G. Marigowda et al., ”Airway lipoxin A₄ generation and lipoxin A₄ receptor expression are decreased in severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 6, pp. 574–582, 2008.

[33] B. D. Levy, C. Bonnans, E. S. Silverman, L. J. Palmer, C. Marigowda, and E. Israel, ”Diminished lipoxin biosynthesis in severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 7, pp. 824–830, 2005.

[34] D. H. Adler, J. D. Cogan, J. A. Phillips et al., ”Inherited human cPLA₂α deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction,” Journal of Clinical Investigation, vol. 118, no. 6, pp. 2121–2131, 2008.
[35] K. A. Reed, D. E. Tucker, A. Aloulou et al., "Functional characterization of mutations in inherited human cPLA2 deficiency," Biochemistry, vol. 50, no. 10, pp. 1731–1738, 2011.

[36] M. Sokolowska, M. Borowiec, A. Ptasinska et al., "83-kDa cytosolic phospholipase A2 group IVa gene promoter polymorphisms in patients with severe asthma: a gene expression and case-control study," Clinical and Experimental Immunology, vol. 150, no. 1, pp. 124–131, 2007.

[37] M. Sokolowska, J. Stefanska, K. Wodz-Naskiewicz, and R. Pawlicki, "Cytosolic phospholipase A2 group IVa influence on GM-CSF expression in human lung cells: a pilot study," Medical Science Monitor, vol. 16, no. 9, pp. BR300–BR306, 2010.

[38] K. A. Whalen, H. Legault, C. Hang et al., "In vitro allergen challenge of peripheral blood induces differential gene expression in mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase A2α overcomes the asthma-associated response," Clinical and Experimental Allergy, vol. 38, no. 10, pp. 1590–1605, 2008.

[39] T. S. Hallstrand, E. Y. Chi, A. G. Singer, M. H. Gelb, and W. R. Henderson, "Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness," American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1072–1078, 2007.

[40] K. Asai, T. Hirabayashi, T. Houjou, N. Uozumi, R. Taguchi, and T. Shimizu, "Human group IVC phospholipase A2 (cPLA2γ): roles in the membrane remodeling and activation induced by oxidative stress," Journal of Biological Chemistry, vol. 278, no. 10, pp. 8809–8814, 2003.

[41] D. J. Mancuso, D. R. Abendschein, C. M. Jenkins et al., "Cardiac ischemia activates calcium-independent phospholipase A2, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition," Journal of Biological Chemistry, vol. 278, no. 25, pp. 22231–22236, 2003.

[42] G. M. Gauvreau, R. M. Watson, and P. M. O’Byrne, "Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation," American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 1, pp. 31–36, 1999.

[43] K. F. Chung, "Evaluation of selective prostaglandin E2 (PGE2) receptor agonists as therapeutic agents for the treatment of asthma," Science’s STKE, vol. 2005, no. 305, pp. 4e7, 2005.

[44] B. Sastre and V. del Pozo, "Role of PGE2 in asthma and nonasthmatic eosinophilic bronchitis," Mediators of Inflammation, vol. 2012, Article ID 645383, 9 pages, 2012.

[45] R. P. Hippi, S. H. Stein, and R. L. Roper, "A new view of prostaglandin E2 regulation of the immune response," Immunology Today, vol. 12, no. 10, pp. 349–352, 1991.

[46] S. Yedgar, M. Krimsky, Y. Cohen, and R. J. Flower, "Treatment of inflammatory diseases by selective eicosanoid inhibition: a double-edged sword?" Trends in Pharmacological Sciences, vol. 28, no. 9, pp. 459–464, 2007.

[47] F. H. Chilton, F. J. Averill, W. C. Hubbard, A. N. Fonteh, M. Triggiani, and M. C. Liu, "Antigen-induced generation of lysophospholipids in human airways," Journal of Experimental Medicine, vol. 183, no. 5, pp. 2235–2245, 1996.

[48] D. L. Bowton, M. C. Seeds, M. B. Fasano, B. Goldsmith, and D. A. Bass, "Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics," American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 2, pp. 421–425, 1997.

[49] W. R. Henderson, E. Y. Chi, J. G. Bollinger et al., "Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model," Journal of Experimental Medicine, vol. 204, no. 4, pp. 865–877, 2007.

[50] T. S. Hallstrand, Y. Lai, Z. Ni et al., "Relationship between levels of secreted phospholipase A2 groups IIa and X in the airways and asthma severity," Clinical and Experimental Allergy, vol. 41, no. 6, pp. 801–810, 2011.

[51] Y. Lai, R. C. Oslund, J. G. Bollinger et al., "Eosinophil cysteiny1 leukotriene synthesis mediated by exogenous secreted phospholipase A2 group X," Journal of Biological Chemistry, vol. 285, no. 53, pp. 41491–41500, 2010.

[52] M. Murakami, Y. Taketomi, H. Sato, and K. Yamamoto, "Secreted phospholipase A2, revisited," Journal of Biochemistry, vol. 150, no. 3, pp. 233–255, 2011.

[53] M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, "Recent progress in phospholipase A2 research: from cells to animals to humans," Progress in Lipid Research, vol. 50, no. 2, pp. 152–192, 2011.

[54] I. Kudo and M. Murakami, "Phospholipase A2 enzymes, Prostaglandins and Other Lipid Mediators, vol. 68–69, pp. 3–58, 2002.

[55] H. K. Tay and A. J. Melendez, "FcyRI-triggered generation of arachidonic acid and eicosanoids requires iPLA2, but not cPLA2, in human mononuclear cells," Journal of Biological Chemistry, vol. 279, no. 21, pp. 22505–22513, 2004.

[56] M. Murakami, S. Masuda, K. Ueda-Semmyo et al., "Group VIB Ca2+ independent phospholipase A2γ promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A2," Journal of Biological Chemistry, vol. 280, no. 14, pp. 14028–14041, 2005.

[57] T. M. McIntyre, S. M. Prescott, and D. M. Stafforini, "The emerging roles of PAF acetylhydrolase," Journal of Lipid Research, vol. 50, pp. S255–S259, 2009.

[58] D. M. Stafforini, T. Numao, A. Tsodikov et al., "Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma," Journal of Clinical Investigation, vol. 103, no. 7, pp. 989–997, 1999.

[59] S. Kruse, X. Q. Mao, A. Heinzmann et al., "The Ile198Thr and Ala379Val variants of plasmatic Paf-acetylhydrolase impair catalytic activities and are associated with atopy and asthma," American Journal of Human Genetics, vol. 66, no. 5, pp. 1522–1530, 2000.

[60] W. R. Henderson, J. Lu, K. M. Poole, G. N. Dietzsch, and E. Y. Chi, "Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model," Journal of Immunology, vol. 164, no. 6, pp. 3360–3367, 2000.

[61] N. R. Henig, M. L. Aitken, M. C. Liu, A. S. Yu, and W. R. Henderson, "Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses," American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 2, part 1, pp. 523–527, 2000.

[62] R. Rivera and J. Chun, "Biological effects of lysophospholipids," Reviews of Physiology, Biochemistry and Pharmacology, vol. 160, pp. 25–46, 2008.

[63] J. A. Urbina, "Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 100, supplement 1, pp. S9–S16, 2006.

[64] B. P. Hurley and B. A. McCormick, "Multiple roles of phospholipase A2 during lung infection and inflammation," Infection and Immunity, vol. 76, no. 6, pp. 2259–2272, 2008.
[65] R. D. Hite, M. C. Seeds, R. B. Jacinto, B. L. Grier, B. M. Waite, and D. A. Bass, "Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A₂ surfactant hydrolysis," *Biochimica et Biophysica Acta*, vol. 1720, no. 1-2, pp. 14–21, 2005.

[66] M. A. Kwatia, C. B. Doyle, W. Cho, G. Enhorning, and S. J. Ackerman, "Combined activities of secretory phospholipases and eosinophil lysophospholipases induce pulmonary surfactant dysfunction by phospholipid hydrolysis," *Journal of Allergy and Clinical Immunology*, vol. 119, no. 4, pp. 838–847, 2007.

[67] S. J. Ackerman, M. A. Kwatia, C. B. Doyle, and G. Enhorning, "Hydrolysis of surfactant phospholipids catalyzed by phospholipase A₂ and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma," *Chest*, vol. 123, no. 3, p. 355S, 2003.

[68] G. Enhorning, "Surfactant in airway disease," *Chest*, vol. 133, no. 4, pp. 975–980, 2008.

[69] M. Hiraoaka, A. Abe, Y. Lu et al., "Lysosomal phospholipase A₂ and phospholipidosis," *Molecular and Cellular Biology*, vol. 26, no. 16, pp. 6139–6148, 2006.

[70] R. S. Koduri, J. O. Grouo, V. J. O. Lainee et al., "Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A₂," *Journal of Biological Chemistry*, vol. 277, no. 8, pp. 5849–5857, 2002.

[71] M. Rouault, C. Le Calvez, E. Boilard et al., "Recombinant pro-
duction and properties of binding of the full set of mouse secreted phospholipases A₂ to the mouse M-type receptor," *Biochemistry*, vol. 46, no. 6, pp. 1647–1662, 2007.

[72] M. Triggiani, F. Granata, A. Frattini, and G. Marone, "Activation of human inflammatory cells by secreted phospholipases A₂;" *Biochimica et Biophysica Acta*, vol. 1761, no. 11, pp. 1289–1300, 2006.

[73] P. Ancian, G. Lambeau, and M. Lazdunski, "Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A₂;" *Biochemistry*, vol. 34, no. 40, pp. 13146–13151, 1995.

[74] F. Granata, R. I. Staiano, S. Loffredo et al., "The role of mast cell-derived secreted phospholipases A₂ in respiratory allergy," *Biochimie*, vol. 92, no. 6, pp. 588–593, 2010.

[75] M. Triggiani, F. Granata, A. Oriente et al., "Secretory phospholipases A₂ induce β-glucuronidase release and IL-6 production from human lung macrophages," *Journal of Immunology*, vol. 164, no. 9, pp. 4908–4915, 2000.

[76] C. C. Silliman, E. E. Moore, G. Zallen et al., "Presence of the M-type sPLA₂ receptor on neutrophils and its role in elastase release and adhesion," *American Journal of Physiology*, vol. 283, no. 4, pp. C1102–C1113, 2002.

[77] A. Gambero, E. C. T. Landucci, M. H. Toyama et al., "Human neutrophil migration in vitro induced by secretory phospholipases A₂: a role for cell surface glycosaminoglycans," *Biochemical Pharmacology*, vol. 63, no. 1, pp. 65–72, 2002.

[78] M. Triggiani, F. Granata, B. Balestrieri et al., "Secretory phospholipases A₂ activate selective functions in human eosino-
phils," *Journal of Immunology*, vol. 170, no. 6, pp. 3279–3288, 2003.

[79] Z. Ni, N. M. Okeley, B. P. Smart, and M. H. Gelb, "Intracellular actions of group IIA secreted phospholipase A₂ and group IVA cytolic phospholipase A₂ contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells," *Journal of Biological Chemistry*, vol. 281, no. 24, pp. 16245–16255, 2006.

[80] M. A. Balboa, R. Pérez, and J. Balsinde, "Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A₂ is regulated by cytosolic phospholipase A₂-derived hydroperoxyeicosatetraenoic acid," *Journal of Immunology*, vol. 171, no. 2, pp. 989–994, 2003.

[81] S. Offer, S. Wedgar, O. Schwob et al., "Negative feedback between secretory and cytosolic phospholipase A₂ and their opposing roles in ovalbumin-induced bronchoconstriction in rats," *American Journal of Physiology*, vol. 288, no. 3, pp. L523–L529, 2005.

[82] A. N. Fonteh, G. I. Atsumi, T. LaPorte, and F. H. Chilton, "Secretory phospholipase A₂ receptor-mediated activation of cytosolic phospholipase A₂ in murine bone marrow-derived mast cells," *Journal of Immunology*, vol. 165, no. 5, pp. 2773–2782, 2000.

[83] Y. J. Jiang, B. Lu, P. C. Choy, and G. M. Hatch, "Regulation of cytosolic phospholipase A₂, cyclooxygenase-1 and -2 expression by PMA, TNFα, LPS and M-CSF in human monocytes and macrophages," *Molecular and Cellular Biochemistry*, vol. 246, no. 1-2, pp. 31–38, 2003.

[84] P. Dieter, A. Kolada, S. Kamionka, A. Schadow, and M. Kaszkin, "Lipopolysaccharide-induced release of arachidonic acid and prostaglandins in liver macrophages: regulation by Group IV cytosolic phospholipase A₂, but not by Group V and Group IIA secretory phospholipase A₂," *Cellular Signalling*, vol. 14, no. 3, pp. 199–204, 2002.

[85] H. Y. Qi and J. H. Shelhamer, "Toll-like receptor 4 signaling reg-
ulates cytosolic phospholipase A₂ activation and lipid generation in lipopolysaccharide-stimulated macrophages," *Journal of Biological Chemistry*, vol. 280, no. 47, pp. 38969–38975, 2005.

[86] W. Tian, G. T. Wijewickrama, J. H. Kim et al., "Mechanism of regulation of group IVA phospholipase A₂ activity by Ser272 phosphorylation," *Journal of Biological Chemistry*, vol. 283, no. 7, pp. 3960–3971, 2008.

[87] X. Zhou, W. Yang, and J. Li, "Ca²⁺- and protein kinase C-dependent signaling pathway for nuclear factor-κB activation, inductive nitric-oxide synthase expression, and tumor necrosis factor-α production in lipopolysaccharide-stimulated rat peritoneal macrophages," *Journal of Biological Chemistry*, vol. 281, no. 42, pp. 31337–31347, 2006.

[88] M. J. Coffey, S. M. Phare, and M. Peters-Golden, "Induction of inducible nitric oxide synthase by lipopolysaccharide/interferon gamma and sepsis down-regulates 5-lipoxygenase metabolism in murine alveolar macrophages," *Experimental Lung Research*, vol. 30, no. 7, pp. 615–633, 2004.

[89] U. T. Shankavaram, D. L. DeWitt, and L. M. Wahl, "Lipopolysac-
charide induction of monocyte matrix metalloproteinases is regulated by the tyrosine phosphorylation of cytosolic phospholipase A₂;" *Journal of Leukocyte Biology*, vol. 64, no. 2, pp. 221–227, 1998.

[90] U. A. Kessen, R. H. Schaloske, D. L. Stephens, K. K. Lucas, and E. A. Dennis, "PGE2 release is independent of upregulation of Group V phospholipase A₂ during long-term stimulation of P388D1 cells with LPS;" *Journal of Lipid Research*, vol. 46, no. 11, pp. 2488–2496, 2005.

[91] P. Shridas, W. M. Bailey, K. R. Talbott, R. C. Oslund, M. H. Gelb, and N. R. Webb, "Group X secretory phospholipase A₂ enhances TLR4 signaling in macrophages," *Journal of Immunology*, vol. 187, no. 1, pp. 482–489, 2011.

[92] K. Hamaguchi, H. Kuwata, K. Yoshihara et al., "Induction of distinct sets of secretory phospholipase A₂ in rodents during
inflammation,” *Biochimica et Biophysica Acta*, vol. 1635, no. 1, pp. 37–47, 2003.

[93] W. R. Hendersen, R. C. Oslund, J. G. Bollinger, X. Ye, Y. T. Tien, J. Xue et al., “Blockade of human group X secreted phospholipase A2-induced airway inflammation and hyperresponsiveness in a mouse asthma model by a selective group X secreted phospholipase A2 inhibitor,” *The Journal of Biological Chemistry*. In press.

[94] N. M. Muñoz, A. Y. Meliton, L. N. Meliton, S. M. Dudek, and A. R. Leff, “Secretory group V phospholipase A2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice,” *American Journal of Physiology*, vol. 296, no. 6, pp. L879–L887, 2009.

[95] N. M. Muñoz, A. Y. Meliton, J. P. Arm, J. V. Bonventre, W. Cho, and A. R. Leff, “Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosenesitized mice,” *The Journal of Immunology*, vol. 179, no. 7, pp. 4800–4807, 2007.

[96] R. Malaviya, J. Ansell, L. Hall et al., “Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice,” *European Journal of Pharmacology*, vol. 539, no. 3, pp. 195–204, 2006.

[97] J. C. McKew, K. L. Lee, M. W. H. Shen et al., “Indole cytosolic phospholipase A2α inhibitors: discovery and in vitro and in vivo characterization of 4-3-[5-chloro-2-[(3,4-dichlorobenzyl)sulfonyl]aminoethyl]-1-(diphenylmethyl)-1H-indol-3-yl]propyl benzoic acid, efpladib,” *Journal of Medicinal Chemistry*, vol. 51, no. 12, pp. 3388–3413, 2008.

[98] K. L. Lee, M. A. Foley, L. Chen et al., “Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2α,” *Journal of Medicinal Chemistry*, vol. 50, no. 6, pp. 1380–1400, 2007.

[99] C. A. Hewson, S. Patel, L. Calzetta et al., “Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 340, no. 3, pp. 656–665, 2012.

[100] F. Hirata, E. Schiffmann, and K. Venkatasubramanian, “A phospholipase A2α inhibitory protein in rabbit neutrophils induced by glucocorticoids,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 77, no. 5, pp. 2533–2536, 1980.

[101] R. De Caterina, R. Sicari, D. Giannessi et al., “Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids,” *Journal of Applied Physiology*, vol. 75, no. 6, pp. 2368–2375, 1993.

[102] X. Huang, R. Pawliczak, X. L. Yao et al., “Characterization of the human p11 promoter sequence,” *Gene*, vol. 310, no. 1-2, pp. 133–142, 2003.

[103] X. L. Yao, M. J. Cowan, M. T. Gladwin, M. M. Lawrence, C. W. Angus, and J. H. Shelhamer, “Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity,” *Journal of Biological Chemistry*, vol. 274, no. 24, pp. 9298–9308, 2003.

[104] X. L. Yao, M. J. Cowan, M. T. Gladwin, M. M. Lawrence, C. W. Angus, and J. H. Shelhamer, “Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity,” *Journal of Biological Chemistry*, vol. 274, no. 24, pp. 17202–17208, 1999.

[105] L. H. K. Lim and S. Pervaiz, “Annexin I: the new face of an old molecule,” *The FASEB Journal*, vol. 21, no. 4, pp. 968–975, 2007.

[106] T. Nakano, O. Ohara, H. Teraoka, and H. Arita, “Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression,” *Journal of Biological Chemistry*, vol. 265, no. 21, pp. 12745–12748, 1990.
